title: The efficacy of inhaled corticosteroids in the management of non asthmatic chronic airflow obstruction.
abstract: OBJECTIVE
  The aims of this investigation were to evaluate the efficacy of regular inhaled beclomethasone in the control of symptoms and lung function with non-asthmatic smoking related obstructive pulmonary disease and to evaluate the relationship between clinical responses to a short course of oral prednisone and longer term outcomes using inhaled steroid.
  
  
  METHODS
  The study was a randomised, double blind, placebo controlled, crossover investigation in 18 patients. The active treatment was inhaled beclomethasone 1000 micrograms given twice daily for three months by metered dose inhaler. At the end of each treatment period, patients received oral prednisone 30 mg/day for ten days. The two treatment phases were separated by a one month washout interval. Peak flow rates, symptom scores and "rescue" bronchodilator use were recorded twice daily. Lung function (FEV1, FVC and lung volumes) and bronchial hyperresponsiveness (PC20 methacholine) were measured at monthly visits. The number of exacerbations requiring intervention therapy were also recorded.
  
  
  RESULTS
  There were no consistent benefits attributable to beclomethasone. Lung function was not significantly better as a result of active treatment. Sputum production improved but other symptom scores were similar during active and placebo therapy. Three patients exhibited an increase in FEV1 of 15% or more during active treatment but did not do so when oral prednisone was administered immediately after the period of placebo treatment. A further three patients showed an improvement in FEV1 of 15% or more with oral prednisone but failed to improve during treatment with inhaled beclomethasone. The predictive value of the "trial of steroid" was 0% and 81.3% for positive and negative outcomes respectively.
  
  
  CONCLUSIONS
  Our results indicate that in non-asthmatic chronic obstructive pulmonary disease inhaled corticosteroid fails to achieve significant improvements in either lung function or symptoms. The response to a "trial of steroid" using oral prednisone is not clinically helpful in selecting the small number of patients who may subsequently benefit from this form of therapy.
authors.affiliation: Department of Medicine, University of Otago, Dunedin.
authors.forename: D
authors.initials: D
authors.lastname: Boothman-Burrell
authors.forename: S G
authors.initials: SG
authors.lastname: Delany
authors.forename: E M
authors.initials: EM
authors.lastname: Flannery
authors.forename: R J
authors.initials: RJ
authors.lastname: Hancox
authors.forename: D R
authors.initials: DR
authors.lastname: Taylor
mesh_terms: D000280:Administration, Inhalation; D000284:Administration, Oral; D001507:Beclomethasone / Q000008:administration & dosage*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000175:diagnosis / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage; D012129:Respiratory Function Tests; D012907:Smoking / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D005938:Glucocorticoids; D001507:Beclomethasone; D011241:Prednisone